cyrilzakka/clinical-trials huggingface dataset:
Internet-delivered CBT for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study

The main goal of this trial is to study the feasibility and effectiveness of internet-delivered cognitive behavior therapy for adolescents with obsessive-compulsive disorder.


Eligibility Criteria:
Inclusion Criteria:

* a primary diagnosis of OCD as defined by DSM-IV TR
* a total score of above 15 on the CY-BOCS
* age between 12 and 17 years
* ability to read and write Swedish
* daily access to the internet
* a parent that is able to co-participate in the treatment
* Participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment
* signed informed consent

Exclusion Criteria:

* diagnosed autism spectrum disorder, psychosis or bipolar disorder
* suicidal ideation
* ongoing substance dependence
* subject not able to read or understand the basics of the ICBT self-help material
* completed CBT for OCD within last 12 months (defined as at least 5 sessions CBT including exposure and response prevention)
* ongoing psychological treatment for OCD or another anxiety disorder
A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC

The Aim of this study is to investigate the amount of tissue required for the successful culture of primary cells from human-derived pancreatic ductal adenocarcinoma which obtained by endoscopic ultrasound-guided fine-needle biopsy wet suction technique

Pancreatic cancer is one of the malignant tumors with the highest mortality rate in the world, with a 5-year survival rate of only 7.2%-9%. Because some patients are resistant to multiple chemotherapy drugs, and there are differences in drug sensitivity between individuals, the current pancreatic ductal adenocarcinoma (PDAC) chemotherapy effect is not satisfactory. In order to improve the efficacy of chemotherapy and achieve precise treatment, it is important to establish an accurate and individualized PDAC research model.

Because most of patients with PDAC have developed to advanced stage at the time of diagnosis, it is not suitable for surgery. That limits our ability to obtain tumor cells seriously. With the development of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) technique, it can be used not only to diagnose diseases, but also to provide specimens for molecular analysis and create valuable preclinical disease research models, so as to guide the selection of the most appropriate individualized treatment. EUS-FNB can obtain lesions without any treatment. Therefore, the preclinical disease research model established by EUS-FNB is more representative of the original tumor.

However, compared with surgical specimens, the specimens obtained by EUS-FNB are smaller in size, which may affect the successful construction of research models in vitro. Therefore, the investigators plan to use EUS-FNB wet suction technique, a modified specimen acquisition method, to obtain PDAC tissue, and use it for primary cell culture, to explore the amount of tissue required for the successful cultivation of human-derived pancreatic cancer primary cells, so as to provide a prerequisite for the successful establishment of human-derived preclinical disease research model.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female, age≥18
2. Imaging examination (US, MRI, CT or PET-CT) of patients confirmed pancreatic lesions, and considered the possibility of PDAC, EUS-FNB was needed for auxiliary diagnosis
3. No chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and palliative chemotherapy, has been performed on patients
4. Agree to attend this study and signed informed consent

Exclusion Criteria:

1. Poor physical condition, including but not limited to hemoglobin ≤ 8.0g/dl, severe cardiopulmonary insufficiency, etc
2. Coagulation dysfunction (platelet count \< 50 × 1012, international standardized ratio \> 1.5), or inability to discontinue anticoagulation therapy
3. High risk for deep sedation
4. Acute pancreatitis in the previous 2 weeks
5. Pregnancy or lactation
6. Any diseases leading to unreliable follow-up
7. Absence of informed consent
Pleth Variability Index as a Predictor for Post-induction Hypotension in Elderly Patients

Hypotension after induction of general anesthesia and before surgical stimulation is a prevalent anesthesia-related side effect. The post-induction hypotension disrupts organ perfusion and may cause organ damage particularly acute kidney injury, cerebrovascular stroke, and myocardial ischemia. Post-induction hypotension occurs with greater frequency and severity in the elderly. This is because of aged-related diminished cardiac reserve and impaired autonomic homeostasis. Pleth variability index (PVI) is a software program that measures the dynamic changes of the PI that occurs during a complete respiratory cycle. Our primary outcome is to determine the predictive ability and the optimal cut-off value of pre-anesthesia PVI for predicting elderly patients who are at risk of developing post-induction hypotension


Eligibility Criteria:
Inclusion Criteria:

* patients with ASA physical status I or II
* patients will receive general anesthesia

Exclusion Criteria:

* Patients with a history of cardiorespiratory disorders
* patients with uncontrolled hypertension or cardiac dysrhythmias
* Patients with renal or hepatic diseases.
* Patients with long-standing diabetes and peripheral vascular diseases.
Fatty Liver Disease in Nordic Countries

A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.


Eligibility Criteria:
Inclusion Criteria:

* Non-alcoholic fatty liver disease and
* Healthy volunteers

Exclusion Criteria:

* Other liver diseases than non-alcoholic fatty liver disease
* Lack of informed consent
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by currently available medications. Cognitive training improves these functions to some degree, but this approach is time- and resource-intensive. The current project aims at enhancing and accelerating the benefits that people with schizophrenia derive from cognitive training by administering nicotine during some of the training sessions. This would provide the proof of principle for a type of treatment intervention to improve cognitive symptoms of schizophrenia.

The current project aims at determining whether the intermittent presence of nicotine during cognitive training exercises in people with schizophrenia will shorten the training period necessary to induce significant and clinically relevant improvement and enhance the improvement seen after a training period of specified length.

Hypothesis 1a: Nicotine administration during training will increase the size of all measured effects of the training intervention, and will accelerate the time course of performance enhancement on the MCCB and training exercise progression parameters.

Hypothesis 1b: The larger training effects in the Nicotine Group will persist beyond the end of the intervention.

Hypothesis 2a: Within-session progress on the training exercises will be larger in the presence of nicotine than in the presence of placebo.

Hypothesis 2b: These acute nicotine-induced performance elevations will persist beyond the presence of nicotine through subsequent non-drug training sessions, giving evidence of an acute facilitation of learning processes.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18-60 years.
* DSM diagnosis of schizophrenia or schizoaffective disorder.
* Ability to give written informed consent.
* Either currently smoking and not attempting to quit, or having smoked no more than 80 cigarettes, cigarillos or cigars in lifetime and not at all within the last year.
* Normal or corrected to normal vision (at least 20/50).
* Four weeks of stable pharmacological treatment (same psychiatric medication at same dose) and no foreseeable changes at enrollment.

Exclusion Criteria:

* Alcohol or substance abuse or dependence other than nicotine within the last 12 months.
* Uncontrolled hypertension (resting systolic blood pressure above 150 or diastolic above 90 mm Hg).
* History of myocardial infarction, heart failure, angina, stroke or severe arrhythmias.
* ECG abnormalities.
* History of neurological conditions such as stroke, seizures, dementia or organic brain syndrome.
* Mental retardation.
* Pregnant, verified by urine pregnancy test for females.
* Breast-feeding.
* Treated with benztropine currently or within the last four weeks.
Alleviating Trunk Low Back Pain, With an Active Medical Device Study (ATLAS)

The aim of the study is to evaluate the reduction of pain by wearing the ATLAS Medical Device in standardized daily activities for patients with Chronic Low Back Pain.

This is an intervention al non blinded study with a crossover design comparing pain evaluated with an Analogue Visual Scale with and without the ATLAS device during 5 standardized daily activities.

This study aims at assessing pain release by wearing a new medical device (ATLAS) in patients affected by chronic low back pain.

Population: patients with chronic low back pain admitted for a 4 weeks rehabilitation program.

Intervention: active rehabilitation and wearing the ATLAS device 60 min per day. The ATLAS study is carried out during the 5 first days of the rehabilitation program.

Primary outcome: Pain intensity evaluation with a 100 mm Visual Analogue Scale (VAS) during 5 standardized activities (the most intensive pain during the 5 activities is recorded), with and without wearing the ATLAS device.

Secondary outcome measures: percentage of patients reporting pain decrease of at least 20 mm on the 100 mm VAS during the 5 standardized activities with the ATLAs device compared without wearing the device. Percentage of relieved patients (percentage of patient reporting pain intensity less than 30 mm on the 100 mm VAS with wearing the device). Pain intensity evaluated with the 100 mm VAS before and after 60 min of wearing the ATLAS device.

Randomization: two groups (i.e. group A and B). Primary outcome is evaluated at day 4 and 5, with a crossover design (Group A: pain is evaluated during activities with the device at day 4 and without the device at day 5. Group B: pain is evaluated during activities without the device at day 4 and with the device at day 5).

Eligibility Criteria:
Inclusion Criteria:

* Chronic low back pain for more than 3 month
* Analogical visual scale superior or egal to 3/10
* BMI \< 30
* 18 \< Age \< 75 years
* Patients who signed the informed consent
* Hospital Anxiety and depression score less than 11

Exclusion Criteria:

* - Neurological or radicular deficit
* Skin pathology of the trunk region
* Antecedent of surgery of spinal fusion
* Implanted neurostimulation treatment
* Scoliosis with Cobb angle \> 30°
* History of vertebral fracture
* BMI \> 30
* Respiratory failure
* Recent rib fracture (less than 3 month)
* Pregnancy or breastfeeding
* Osteoporosis
* Refusal to participate to the study
Predictive Model for Postoperative Mortality

Surgery has risk of morbidity and mortality. Risk factors include: patient factors; surgical factors; and anesthetic factors. The risk is much higher in emergency cases. The study of relevant risk factors can lead to improvement in patient management and reduction in mortality.

Objective: To identify risk factors for postoperative mortality within 3 days in adult patients undergoing emergency surgery and construct a predictive model.

Methods: This will be a retrospective, exploratory and analytical study. All medical records of adult patients undergoing emergency surgery between January 2013 to December 2014 will be used to analyze for relevant risk factors using binary logistic regression analysis. A predictive model to predict postoperative morbidity within 3 days will be constructed.

Eligibility Criteria:
Inclusion Criteria:

* Emergency surgery
* Age =\> 18 years

Exclusion Criteria:

* Caesarean section
* Incomplete medical record
Elbow Arthroscopy Data Analysis

The purpose of this study is to evaluate preoperative objective measurements and operative objective measurements to determine if there is any effect to postoperative outcomes. Patients who were 13 years old or greater at the time of arthroscopic osteocapsular release were followed clinically and radiographically to determine best practice and optimal treatment and technique, risk and rate of complication, and postoperative outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. English speaking
2. \>13 years of age
3. Patients treated with elbow arthroscopy for elbow arthritis, radiocapitellar plica, osteochondritis dissecans or lateral epicondylitis.

Exclusion Criteria:

1. Non-English speaking
2. \<13 years of age
Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy

Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin treatment once a year compared to 2 and 3 times a year. All participants also receive anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will be followed for 12 months. The primary endpoint is seizure freedom defined as no seizures during the last fourth months of the trial.

Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin treatment once a year compared to 2 and 3 times a year. All participants also receive anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will be followed for 12 months.The primary endpoint is seizure freedom defined as no seizures during the last fourth months of the trial.

Eligibility Criteria:
Inclusion Criteria:

* Age 5 years and above
* Signed informed consent form
* Normal neurological development until onset of epilepsy
* Onset of epilepsy between ages of 5 and 18 years
* Presence of microfilaria in skin snip and/or antibodies against Ov16

Exclusion Criteria:

* Ivermectin intake the last 9 months
* Pregnancy or breastfeeding
* Known or suspected allergy to Ivermectin
* Loa Loa microfilariae in blood
* Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with a history of cerebral malaria, meningitis or encephalitis)
* Concomitant acute illness or chronic medication use
* Chronic alcohol/substance use
Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin

The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of sitagliptin in healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects aged 20 - 50 years
* A body mass index (BMI) in the range 17-28 kg/m2
* Fasting plasma glucose levels in the range 70-110 mg/dL
* Sufficient ability to understand the nature of the study and any hazards of participating in it
* Provide written informed consent after being fully informed about the study procedures

Exclusion Criteria:

* Presence or history of severe adverse reaction to any drug (e.g., sitagliptin) or a history of severe allergic disease
* Clinically relevant abnormal medical history that could interfere with the objectives of the study
* A subject who has the following screening laboratory test results; creatinine clearance (calculated by Cockcroft-Gault equation) \< 80 mL/min
* History of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
* A subject whose SBP is over 150 mmHg or below 100 mmHg and DBP is over 95 mmHg or below 65 mmHg
* Presence or history of drug abuse
* Participation in other clinical trial within 2 months
* Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter medication within 1 week before first dose
* Blood donation during 2 months or apheresis during 1 month before the study
* Presence or history of alcohol abuse
* Users of nicotine-containing substances within the previous three months
* Use of grapefruit juice, alcohol or smoking during restriction period
* Subject judged not eligible for study participation by investigator
Vertical Soft Tissue Augmentation With CTG vs ADM

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.

Eligibility Criteria:
Inclusion criteria:

* Age ≥ 18 years
* Periodontally and systemically healthy
* Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
* Presence of single functional dental implant in the anterior with a PSTD
* Implants diagnosed as healthy (Berglundh et al., 2018)

Exclusion criteria are:

* Contraindications for surgery
* Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
* Patients pregnant or attempting to get pregnant (self-reported)
* Untreated periodontitis
* Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
* Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded
* History of soft tissue grafting at the implant site within the last 6 months
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Provision of a written informed consent
* Men or women who are \>=18 years of age
* Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
* Completed the last two visits of randomized treatment period in GALLANT 2/22, 5, 7, 8 or 14 studies.

Exclusion Criteria:

* Type 1 diabetes
* New York Heart Association heart failure Class III or IV
* Treatment with chronic insulin
* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
* Creatinine levels above twice the normal range
* Creatine kinase above 3 times the upper limit of normal
* Previous enrollment in this long-term extension study
* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Assessing People's Hospital Outpatient Appointment Preferences in the United Kingdom

The sustainability of the United Kingdom's National Health Service's (NHS) is threatened immediately by Covid-19 and continually by an increasing prevalence of long-conditions that cannot be cured but can be maintained. Shifting traditional face-to-face outpatient appointments to remote video consultations may help the NHS continue to serve patients efficiently. While much research has examined healthcare providers' attitudes and beliefs about remote video consultations, less has attempted to understand how NHS service providers should invite patients to attend them. The present study examines how the framing of an invitation to attend a hospital outpatient appointment by video influences the proportion of people who agree to attend by video. It also explores some of the barriers and facilitators people may experience to attending appointments by video across diagnostic complexities and age groups. The results of this study should help hospitals better present patients with the option to attend video consultations where appropriate, and provide support to mitigate common barriers to people's willingness to give video consultations a go.


Eligibility Criteria:
Inclusion Criteria:

All participants will:

* be 18 years old or older;
* be resident in the United Kingdom; and
* indicate having been diagnosed with a chronic diseases such as diabetes, heart disease, stroke etc.

Exclusion Criteria:

* be less than 18 years old;
* not be resident in the United Kingdom; and
* not indicate having been diagnosed with a chronic diseases such as diabetes, heart disease, stroke etc.
Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Hypercapnic ARF

The study´s intention is to evaluate the feasibility, safety and effectiveness of a pump driven extracorporeal device for removal of carbon dioxide from the blood in oder to avoid intubation and invasive mechanical ventilation in patients with acute respiratory failure retaining carbon dioxide due to the failure of their ventilatory muscle pump and not responding to prior non-invasive mask ventilation.

The study´s intention is to evaluate the feasibility, safety and effectiveness of a pump driven extracorporeal device for removal of carbon dioxide from the blood in oder to avoid intubation and invasive mechanical ventilation in patients with acute respiratory failure retaining carbon dioxide due to the failure of their ventilatory muscle pump and not responding to prior non-invasive mask ventilation. Since intubation with subsequent (prolonged) invasive mechanical ventilation is associated with considerable side effects this new strategy has the potential to improve overall clinical outcome in this selected patient group.

Eligibility Criteria:
Inclusion Criteria:

* acute or acute-on-chronic hypercapnic respiratory insufficiency (pH ≤ 7,35, PaCO2 \> 45 mmHg)
* failure of noninvasive ventilation
* fulfilling criteria for endotracheal intubation

Exclusion Criteria:

* under 18 years of age
* prior inclusion in other interventional study
* pregnancy
* heparin allergy or heparin-induced thrombocytopenia type 2
* on home non-invasive ventilator
* "Do not resuscitate" order or moribund condition
* life expectancy less than 6 months
* no informed consent available